Dr Ira Shoulson
Dr Ira Shoulson has served as a director of our company since May 2014 and is the Chairman of our Research and Development Advisory Board. Dr Shoulson is founder and principal of Grey Matter Technologies LLC. He is currently adjunct professor of Neurology at Georgetown University (Washington, DC) and the University of Rochester (Rochester, NY)
From 2011 to 2018, Dr Shoulson was Professor of Neurology, Pharmacology and Human Science and Director of the Program for Regulatory Science Medicine (PRSM) at Georgetown University where he was principal investigator of the FDA-Georgetown University Collaborating Center of Excellence in Regulatory Science and Innovation.
From 1990 to 2011, Dr Shoulson was the Louis C. Lasagna Professor of Experimental Therapeutics and Professor of Neurology, Pharmacology and Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, New York.
He received his MD degree with honours (1971) and post-doctoral training in medicine (1971-73) and neurology (1975-77) at the University of Rochester and in experimental therapeutics at the National Institutes of Health (1973-75). Dr Shoulson founded the Parkinson Study Group in 1985 and the Huntington Study Group in 1994 -- international consortia devoted to research and development of treatments for Parkinson disease, Huntington disease, and related neurodegenerative and neurogenetic disorders. He was a key investigator in the US-Venuzuela Collaborative Huntington Disease Project, which identified the gene responsible for this fatal hereditary disorder. Dr Shoulson has served as a principal investigator of the National Institutes of Health-sponsored trials "Deprenyl and Tocopherol Antioxdative Therapy of Parkinsonism" (DATATOP), the "Prospective Huntington At Risk Observational Study" (PHAROS), and in the leadership of more than 40 other multi-center clinical research studies. He played an instrumental role in the development of 10 new drugs for neurological disorders, including for Parkinson disease ( selegiline, lazabemide, pramipexole, entacapone, clozapine, rasagiline, rotigitine) Huntington disease (tetrabenazine, dutetetrabenazine) and attention deficit disorder (Concerta). He was formerly a health policy fellow in the US Senate, a member of the National Institute of Neurological Disorders and Stroke Council, president of the American Society for Experimental NeuroTherapeutics (ASENT), and associate editor of JAMA Neurology.
In 2016, he was recipient of the Michael J. Fox Foundation Pritzker Prize, in recognition of his leadership in research and education for Parkinson disease. Dr Shoulson is an elected member of the National Academy of Medicine of the National Academy of Sciences. He has authored more than 325 scientific reports.